07:02 AM EDT, 10/10/2024 (MT Newswires) -- Eli Lilly ( LLY ) has started a legal campaign against companies that were producing and selling copycat versions of its weight-loss drugs during a recent shortage, Bloomberg reported Thursday.

Since December 2022, the FDA has allowed compounding pharmacies to produce and distribute copies of Lilly's drugs to address the shortage, but the designation was lifted on Oct.2, the report said.

Lilly is sending hundreds of cease-and-desist letters to telehealth companies, compounding pharmacies, and medical spas, demanding they halt the production and sale of these copycat products, the report said, citing the drugmaker.

Lilly said some patients may still face difficulties in obtaining brand-name drugs in the coming months due to supply chain challenges, the report said.

Lilly did not immediately respond to requests for comment from MT Newswires.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 920.25, Change: +0.51, Percent Change: +0.06